SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,878.00    130.00 (4.73%)
Bid:
2,846.00
Ask:
2,862.00
Spread: 16.00 (0.562%)
Market Cap: £1.59b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Acquisition

1 May 2015 07:00

RNS Number : 9497L
Oxford Instruments PLC
01 May 2015
 



 

Release date: 1 May 2015

 

Oxford Instruments plc

Acquisition of Medical Imaging Resources, Inc.

 

Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces the acquisition of Medical Imaging Resources, Inc. (MIR).

 

Founded in 1990 in Ann Arbor Michigan by CEO John Vartanian, MIR specialises in the build, lease and service of mobile medical imaging labs ("mobiles").

 

The mobile labs are built in MIR's factory, with Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) systems from Siemens, GE, Philips and Toshiba. These are leased to customers across the USA. MIR is also responsible for servicing its mobiles. Customers include hospitals and clinics that need additional capacity or that wish to trial MRI or CT machines without committing to the infrastructure and cost associated with a permanent unit.

 

MIR will form a part of OIHealthcare, within the Group's Service sector, which already services GE MRI and CT machines in the USA. There are a number of synergies with OIHealthcare:

 

· This will be a significant step to making OIHealthcare a multi-skilled independent service provider able to support large individual service contracts;

· Access to OIHealthcare's parts and its purchasing power for complete systems will lower MIR's operating costs;

· There will be overheads savings in those areas where duplication is eliminated;

· MIR currently sub-contracts a significant portion of the service work for its mobiles. OIHealthcare staff are located in numerous states and once trained will take over the work and will be able to bring the margin in-house.

 

Consideration, which will be satisfied from existing facilities, comprises $10.4 million (c. £6.8 million) on completion followed by a further $10.1 million (c. £6.6 million) earn-out payable one year later. MIR has approximately $3.0 million (c. £2.0 million) net debt at completion.

 

In the year to 31 December 2014, MIR had sales of $16.6 million (c. £10.8 million), profit before tax of $2.8 million (c. £1.8 million) and EBITDA of $5.6 million (c. £3.6 million). At 31 December 2014, MIR had gross assets of $9.4 million (c. £6.1 million).

 

 

 

Jonathan Flint (Chief Executive) and Kevin Boyd (Finance Director) will host a conference call for analysts and investors on this announcement at 9:30 am (UK time), today 1 May. To join the call, please use the dial-in numbers below:

 

Dial: +44 (0)20 3139 4830

PIN: 89662683#

 

 

 

- Ends -

 

Enquiries:

 

 

Oxford Instruments plc Tel: 01865 393200

Jonathan Flint, Chief Executive

Kevin Boyd, Group Finance Director

 

MHP Tel: 020 3128 8100

Rachel Hirst / Jack Holden

 

Issued for and on behalf of Oxford Instruments plc

 

 

 

Notes to Editors  

 

About Oxford Instruments plc

Oxford Instruments designs, supplies and supports high-technology tools and systems with a focus on research and industrial applications. Innovation has been the driving force behind Oxford Instruments' growth and success for over 50 years, and its strategy is to effect the successful commercialisation of these ideas by bringing them to market in a timely and customer-focused fashion.

The first technology business to be spun out from Oxford University, Oxford Instruments objective is to be the leading provider of new generation tools and systems for the research and industrial sectors with a focus on nanotechnology. Its key market sectors include nano-fabrication and nano-materials. The company's strategy is to expand the business into the life sciences arena, where nanotechnology and biotechnology intersect.

This involves the combination of core technologies in areas such as low temperature, high magnetic field and ultra high vacuum environments; Nuclear Magnetic Resonance; x-ray, electron, laser and optical based metrology; atomic force microscopy; optical imaging; advanced growth, deposition and etching.

Oxford Instruments aims to pursue responsible development and deeper understanding of our world through science and technology. Its products, expertise, and ideas address global issues such as energy, environment, security and health.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQEAFLEDSDSEAF
Date   Source Headline
2nd Jan 201911:33 amPRNHolding(s) in Company
17th Dec 20181:22 pmPRNHolding(s) in Company
12th Dec 201810:25 amPRNDirector/PDMR Shareholding
11th Dec 20185:07 pmPRNHolding(s) in Company
10th Dec 20189:34 amPRNHolding(s) in Company
3rd Dec 20183:20 pmPRNHolding(s) in Company
28th Nov 20189:31 amPRNHolding(s) in Company
26th Nov 201810:17 amPRNAppointment of Chairman
22nd Nov 201810:26 amPRNHolding(s) in Company
13th Nov 20189:49 amPRNDirector/PDMR Shareholding
13th Nov 20187:00 amRNSHalf-year Report
11th Oct 201810:38 amPRNDirector/PDMR Shareholding
11th Sep 20184:07 pmPRNResult of AGM
11th Sep 20181:47 pmPRNDirector/PDMR Shareholding
11th Sep 20187:00 amRNSInterim Chairman's AGM Statement 2018
13th Aug 20183:27 pmPRNDirector/PDMR Shareholding
24th Jul 201812:00 pmPRNHolding(s) in Company
23rd Jul 20181:00 pmRNSDeath of Chairman
19th Jul 20187:00 amPRNHolding(s) in Company
11th Jul 201812:15 pmPRNHolding(s) in Company
11th Jul 201811:51 amPRNDirector/PDMR Shareholding
5th Jul 201811:09 amPRNBlocklisting - Interim Review
4th Jul 201812:02 pmPRNDirector/PDMR Shareholding
12th Jun 201810:46 amPRNDirector/PDMR Shareholding
12th Jun 20187:00 amRNSFinal Results
11th May 201812:07 pmPRNDirector/PDMR Shareholding
11th Apr 20187:00 amRNSTrading Update
9th Apr 201811:03 amPRNDirector/PDMR Shareholding
1st Mar 201812:35 pmPRNDirector/PDMR Shareholding
8th Feb 20189:36 amPRNDirector/PDMR Shareholding
1st Feb 201811:21 amPRNTotal Voting Rights
9th Jan 20189:59 amPRNBlocklisting - Interim Review
5th Dec 201710:43 amPRNTotal Voting Rights
16th Nov 20179:22 amPRNHolding(s) in Company
14th Nov 20177:00 amRNSHalf-year Report
31st Oct 201710:02 amPRNDirectorate Change
3rd Oct 201711:42 amPRNTotal Voting Rights
26th Sep 20172:02 pmPRNCorrection : Director/PDMR Shareholding
26th Sep 201710:57 amPRNDirector/PDMR Shareholding
12th Sep 201711:59 amPRNResult of AGM
12th Sep 20177:00 amRNSAGM Statement
4th Sep 201711:14 amPRNTotal Voting Rights
17th Aug 201710:26 amPRNHolding(s) in Company
8th Aug 201712:55 pmPRNTotal Voting Rights
4th Jul 201710:24 amPRNBlocklisting - Interim Review
4th Jul 201710:12 amPRNTotal Voting Rights
3rd Jul 20172:48 pmRNSCompletion of Sale of Industrial Analysis to HHT
13th Jun 20178:41 amRNSAppointment of Senior Independent Director
13th Jun 20177:03 amRNSAppointment of Senior Independent Director
13th Jun 20177:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.